Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study of Optimal Dose of Haloperidol

NCT01639599 is registered in ClinicalTrials.gov with The Catholic University of Korea as lead sponsor.

NCT NCT01639599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01639599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study of Optimal Dose of Haloperidol
Lead sponsor
The Catholic University of Korea
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2012
Completion date
May 31, 2013
Enrollment
150 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gynecological disease